PhaseBio goes public in downsized offering of $46 million
The company, developing a reversal agent for an antiplatelet therapy in-licensed from AstraZeneca, had proposed an IPO at $12-14 per share.
Galera Therapeutics raises $150M Series C round to fund clinical development
The company plans to use the money for a registrational Phase III study of its severe oral mucositis drug, which showed positive results in Phase IIb trial data presented in June.
presented by
Could QuantalX’s Device Make Managing Brain Health Easier?
CEO and neuroscientist Dr. Iftach Dolev on how the new device can bring a powerful tool to psychiatrists and neurologists alike.